Aduro BioTech Inc (NASDAQ:ADRO) COO Gregory W. Schafer sold 20,000 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.34, for a total value of $186,800.00. Following the completion of the transaction, the chief operating officer now owns 155,676 shares in the company, valued at $1,454,013.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Aduro BioTech Inc (ADRO) traded down $0.40 on Thursday, reaching $8.20. The company’s stock had a trading volume of 658,800 shares, compared to its average volume of 408,334. Aduro BioTech Inc has a 12 month low of $6.01 and a 12 month high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same period in the prior year, the firm posted ($0.54) EPS. The business’s revenue was up .0% compared to the same quarter last year. equities analysts forecast that Aduro BioTech Inc will post -1.28 earnings per share for the current year.
A number of large investors have recently bought and sold shares of ADRO. Harvard Management Co. Inc. purchased a new stake in shares of Aduro BioTech in the third quarter valued at approximately $69,418,000. JPMorgan Chase & Co. grew its holdings in shares of Aduro BioTech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Aduro BioTech by 762.1% during the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares during the last quarter. Nexthera Capital LP purchased a new position in shares of Aduro BioTech during the second quarter worth about $1,767,000. Finally, Baillie Gifford & Co. lifted its position in Aduro BioTech by 45.8% in the second quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock valued at $4,819,000 after purchasing an additional 132,700 shares during the period. Institutional investors own 45.19% of the company’s stock.
Several equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Aduro BioTech in a report on Wednesday, September 27th. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, Oppenheimer initiated coverage on Aduro BioTech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Aduro BioTech currently has a consensus rating of “Buy” and a consensus price target of $19.14.
TRADEMARK VIOLATION WARNING: “Insider Selling: Aduro BioTech Inc (ADRO) COO Sells $186,800.00 in Stock” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2017/12/07/insider-selling-aduro-biotech-inc-adro-coo-sells-186800-00-in-stock.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.